Rifampin Capsules — Class II drug recall D-1343-2022
Terminated recall by Lupin Pharmaceuticals Inc., reported 2022-08-24, distributed nationwide. CGMP Deviations:OOS result was observed in 1-Methyl-4-Nitroso Piperazine (MNP) impurity.
| Recall number | D-1343-2022 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Lupin Pharmaceuticals Inc., Baltimore, MD, United States |
| Recall initiated | 2022-07-28 |
| Classified | 2022-08-16 |
| Reported by FDA | 2022-08-24 |
| Terminated | 2023-10-05 |
| Distributed | Nationwide (US) |
| Quantity | 7,872 |
| Reason classes | cgmp, specification failure |
| NDC | 68180-0658, 68180-0658-01, 68180-0658-06, 68180-0659, 68180-0659-01, 68180-0659-06, 68180-0659-07 |
| Lot numbers | A200170 |
| Expiration dates | 2023-12-20 |
Product
Rifampin Capsules, USP, 150 mg, 30 count HDPE bottles, Rx Only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202 NDC: 68180-658-06
Reason for recall
CGMP Deviations:OOS result was observed in 1-Methyl-4-Nitroso Piperazine (MNP) impurity.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1343-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.